P. Kostenuik

发表

Skeletal muscle adaptations to microgravity exposure in the mouse.

B. Harrison, D. Allen, B. Girten, 2003, Journal of applied physiology.

Influence of Fatigue Loading and Bone Turnover on Bone Strength and Pattern of Experimental Fractures of the Tibia in Mice

P. Kostenuik, M. Gerbaix, N. Bonnet, 2016, Calcified Tissue International.

Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis

Qing Chen, Tom Boone, Raj Haldankar, 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Bone cell matrix promotes the adhesion of human prostatic carcinoma cells via the α2β1 integrin

P. Kostenuik, F. Orr, Gurmit Singh, 2004, Clinical & Experimental Metastasis.

Growth Factor Regulation of Fracture Repair

T A Einhorn, P. Kostenuik, T. Einhorn, 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Stimulation of bone resorption results in a selective increase in the growth rate of spontaneously metastatic Walker 256 cancer cells in bone

P. Kostenuik, F. Orr, Gurmit Singh, 1992, Clinical & Experimental Metastasis.

Bone and hormonal changes induced by skeletal unloading in the mature male rat.

P. Kostenuik, A. Bouraoui, D. Bikle, 1999, The American journal of physiology.

Transforming growth factor β upregulates the integrin-mediated adhesion of human prostatic carcinoma cells to type I collagen

P. Kostenuik, F. Orr, Gurmit Singh, 2004, Clinical & Experimental Metastasis.

and platelets erythrocytes, C57BL/6 mouse. II. Activation, cytokines, the Contribution: Effects of spaceflight on immunity in Genetic Models in Applied Physiology: Selected

L. Stodieck, P. Kostenuik, S. Morony, 2006 .

Fracture healing physiology and the quest for therapies for delayed healing and nonunion

P. Kostenuik, Faisal M Mirza, 2016, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats

P. Kostenuik, M. Stolina, H. Ke, 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Sustained Modeling‐Based Bone Formation During Adulthood in Cynomolgus Monkeys May Contribute to Continuous BMD Gains With Denosumab

P. Kostenuik, R. Baron, D. Dempster, 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys.

Ian Pyrah, P. Kostenuik, Susan Y. Smith, 2011, Bone.

Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption

P. Kostenuik, R. Guldberg, G. Hattersley, 2017, Osteoporosis International.

Effects of Denosumab, Alendronate, or Denosumab Following Alendronate on Bone Turnover, Calcium Homeostasis, Bone Mass and Bone Strength in Ovariectomized Cynomolgus Monkeys

P. Kostenuik, Susan Y. Smith, J. Jolette, 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Novel Genetic Models of Osteoporosis by Overexpression of Human RANKL in Transgenic Mice

P. Kostenuik, M. Stolina, E. Douni, 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

RANKL Inhibitors Induce Osteonecrosis of the Jaw in Mice With Periapical Disease

S. Dry, P. Kostenuik, S. Tetradis, 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody.

P. Kostenuik, Susan Y. Smith, I. Pyrah, 2011, Bone.

Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.

P. Kostenuik, 2005, Current opinion in pharmacology.

Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease

P. Kostenuik, T. Bateman, S. Morony, 2008, Osteoporosis International.

Soluble RANKL Induces High Bone Turnover and Decreases Bone Volume, Density, and Strength in Mice

P. Kostenuik, T. Bateman, S. Morony, 2008, Calcified Tissue International.

Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock‐In Mice That Express Chimeric (Murine/Human) RANKL

P. Kostenuik, S. Morony, W. Dougall, 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin.

P. Kostenuik, M. Stolina, H. Ke, 2009, Bone.

Mechanisms of tumor metastasis to bone.

P. Kostenuik, F. Orr, D. Goltzman, 2000, Critical reviews in eukaryotic gene expression.

Skeletal unloading inhibits the in vitro proliferation and differentiation of rat osteoprogenitor cells.

P. Kostenuik, D. Bikle, E. Morey-Holton, 1997, American journal of physiology. Endocrinology and metabolism.

Revisiting the seed and soil theory of bone metastasis: new tools, same answer.

P. Kostenuik, 2004, Journal of musculoskeletal & neuronal interactions.

Mechanisms involved in the metastasis of cancer to bone

P. Kostenuik, F. Orr, Gurmit Singh, 2004, Breast Cancer Research and Treatment.

OPG, RANK and RANKL in Bone Metastasis and Cancer-Associated Osteolysis

P. Kostenuik, 2004 .

Tumor-bone interactions in skeletal metastasis.

P. Kostenuik, F. Orr, O. Sanchez-Sweatman, 1995, Clinical orthopaedics and related research.

Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption.

P. Kostenuik, V. Shalhoub, Victoria Shalhoub, 2001, Current pharmaceutical design.

Integrin αvβ3 as a PET Imaging Biomarker for Osteoclast Number in Mouse Models of Negative and Positive Osteoclast Regulation

P. Kostenuik, C. Anderson, T. Wadas, 2012, Molecular Imaging and Biology.

Sclerostin antibody stimulates periodontal regeneration in large alveolar bone defects

P. Kostenuik, W. Giannobile, E. Doherty, 2020, Scientific Reports.

RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis.

P. Kostenuik, J. Cirelli, Q. Jin, 2007, Journal of periodontology.

Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in ldlr(−/−) Mice

P. Kostenuik, S. Morony, M. Stolina, 2008, Circulation.

Are Osteoclasts Needed for the Bone Anabolic Response to Parathyroid Hormone?

P. Kostenuik, M. Stolina, P. Baldock, 2010, The Journal of Biological Chemistry.

Osteoprotegerin is an effective countermeasure for spaceflight-induced bone loss in mice.

L. Stodieck, P. Kostenuik, T. Bateman, 2015, Bone.

Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody.

P. Kostenuik, M. Stolina, H. Ke, 2014, Endocrinology.

Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.

P. Kostenuik, M. Stolina, H. Ke, 2014, Bone.

Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.

P. Kostenuik, M. Stolina, H. Ke, 2011, Endocrinology.

OPG-Fc Treatment in Growing Pigs Leads to Rapid Reductions in Bone Resorption Markers, Serum Calcium, and Bone Formation Markers

P. Kostenuik, P. Zysset, E. Mayrhofer, 2011, Hormone and Metabolic Research.

Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis.

H. Bergmeister, P. Kostenuik, G. Kollias, 2004, The American journal of pathology.

Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.

P. Kostenuik, K. Kyvik, J. Hjelmborg, 2005, Bone.

Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women.

P. Kostenuik, B. Riggs, S. Khosla, 2010, The Journal of clinical endocrinology and metabolism.

Infrequent Delivery of a Long‐Acting PTH‐Fc Fusion Protein Has Potent Anabolic Effects on Cortical and Cancellous Bone

Steven W. Martin, P. Kostenuik, S. Morony, 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models.

P. Kostenuik, M. Stolina, G. Schett, 2005, Arthritis and rheumatism.

OPG and PTH-(1–34) Have Additive Effects on Bone Density and Mechanical Strength in Osteopenic Ovariectomized Rats

P. Kostenuik, S. Morony, D. Lacey, 2001 .

RANKL Inhibition with Osteoprotegerin Increases Bone Strength by Improving Cortical and Trabecular bone Architecture in Ovariectomized Rats

P. Kostenuik, M. Stolina, H. Ke, 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL.

P. Kostenuik, M. Skalicky, L. Hofbauer, 2009, Arthritis and rheumatism.

RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFα or anti-IL-1 therapies

P. Kostenuik, M. Stolina, G. Schett, 2009, Arthritis research & therapy.

CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin

P. Kostenuik, S. Morony, D. Lacey, 2004, Gut.

Comparison of Effects of the Bisphosphonate Alendronate Versus the RANKL Inhibitor Denosumab on Murine Fracture Healing

Thomas A Einhorn, Elise F Morgan, Louis C Gerstenfeld, 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Combination therapy with BMP-2 and a systemic RANKL inhibitor enhances bone healing in a mouse critical-sized femoral defect.

P. Kostenuik, J. Lieberman, O. Sugiyama, 2016, Bone.

Bone cell matrix promotes the adhesion of human prostatic carcinoma cells via the alpha 2 beta 1 integrin.

P. Kostenuik, F. Orr, O. Sanchez-Sweatman, 1996, Clinical & experimental metastasis.

Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells

P. Kostenuik, L. Hofbauer, V. Sexl, 2017, Scientific Reports.

Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis.

P. Kostenuik, S. Morony, D. Lacey, 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

expressionof spaceflight on murine skeletal muscle gene

B. Harrison, L. Stodieck, P. Kostenuik, 2013 .

Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice.

P. Kostenuik, L. Hofbauer, R. Erben, 2009, The American journal of pathology.

CHAPTER 18 RANKL INHIBITION: FROM MICE TO MEN (AND WOMEN)

P. Kostenuik, W. Dougall, M. Stolina, 2007 .

Continuous RANKL Inhibition in Osteoprotegerin Transgenic Mice and Rats Suppresses Bone Resorption without Impairing Lymphorganogenesis or Functional Immune Responses1

P. Kostenuik, I. Sarosi, M. Stolina, 2007, The Journal of Immunology.

Functional Immune Responses Impairing Lymphorganogenesis or Suppresses Bone Resorption without Osteoprotegerin Transgenic Mice and Rats Continuous RANKL Inhibition in

P. Kostenuik, I. Sarosi, M. Stolina, 2007 .

Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis.

P. Kostenuik, S. Morony, W. J. Boyle, 2002, Arthritis and rheumatism.

RANKL is a Marker and Mediator of Local and Systemic Bone Loss in Two Rat Models of Inflammatory Arthritis

P. Kostenuik, M. Stolina, G. Schett, 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Local delivery of osteoprotegerin inhibits mechanically mediated bone modeling in orthodontic tooth movement.

P. Kostenuik, W. Giannobile, S. Kapila, 2007, Bone.

The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys

P. Kostenuik, M. Ominsky, S. Smith, 2007, Osteoporosis International.

RANKL Inhibition: A Novel Strategy to Decrease Femoral Head Deformity After Ischemic Osteonecrosis

P. Kostenuik, Stephanie Morgan-Bagley, Harry KW Kim, 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

The Receptor Activator of Nuclear Factor-κB Ligand Inhibitor Osteoprotegerin Is a Bone-Protective Agent in a Rat Model of Chronic Renal Insufficiency and Hyperparathyroidism

P. Kostenuik, S. Morony, D. Lacey, 2005, Calcified Tissue International.

Selective inhibition of receptor activator of NF-κB ligand (RANKL) in hematopoietic cells improves outcome after experimental myocardial infarction

P. Kostenuik, L. Hofbauer, R. Erben, 2018, Journal of Molecular Medicine.

Immobilization of Denosumab on Titanium Affects Osteoclastogenesis of Human Peripheral Blood Monocytes

P. Kostenuik, Marina Unger, M. van Griensven, 2019, International journal of molecular sciences.

Laboratory Investigations The Receptor Activator of Nuclear Factor-jB Ligand Inhibitor Osteoprotegerin Is a Bone-Protective Agent in a Rat Model of Chronic Renal Insufficiency and Hyperparathyroidism

P. Kostenuik, S. Morony, D. Lacey, 2006 .

OPG‐Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice

S. Dry, P. Kostenuik, R. Boyce, 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Abaloparatide, a PTH receptor agonist with homology to PTHrP, enhances callus bridging and biomechanical properties in rats with femoral fracture

P. Kostenuik, B. Lanske, G. Hattersley, 2019, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

Tumor necrosis factor alpha and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis.

P. Kostenuik, M. Stolina, G. Schett, 2009, Arthritis and rheumatism.

The Evolving Systemic and Local Biomarker Milieu at Different Stages of Disease Progression in Rat Adjuvant-Induced Arthritis

P. Kostenuik, M. Stolina, B. Bolon, 2009, Journal of Clinical Immunology.

The evolving systemic and local biomarker milieu at different stages of disease progression in rat collagen-induced arthritis

P. Kostenuik, M. Stolina, B. Bolon, 2008 .

The evolving systemic and local biomarker milieu at different stages of disease progression in rat collagen-induced arthritis.

P. Kostenuik, M. Stolina, B. Bolon, 2008, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

Hypocalcaemia in patients with metastatic bone disease treated with denosumab.

A. Shaywitz, P. Kostenuik, F. Saad, 2015, European journal of cancer.

Sustained Antiresorptive Effects After a Single Treatment With Human Recombinant Osteoprotegerin (OPG): A Pharmacodynamic and Pharmacokinetic Analysis in Rats

Steven W. Martin, P. Kostenuik, S. Morony, 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.

P. Kostenuik, S. Morony, C. Capparelli, 2005, Endocrinology.

Sclerostin-Neutralizing Antibody Enhances Bone Regeneration Around Oral Implants.

P. Kostenuik, Q. Jin, W. Giannobile, 2018, Tissue engineering. Part A.

The RANKL Inhibitor Osteoprotegerin (OPG) Causes Greater Suppression of Bone Resorption and Hypercalcemia Compared to Bisphosphonates in Two Models of Humoral Hypercalcemia of Malignancy

P. Kostenuik, S. Morony, C. Capparelli, 2005 .

OPG Treatment Prevents Bone Loss During Lactation But Does Not Affect Milk Production or Maternal Calcium Metabolism.

P. Kostenuik, J. Wysolmerski, C. Dumitru, 2015, Endocrinology.

Serum calcium concentration is maintained when bone resorption is suppressed by osteoprotegerin in young growing male rats.

Emily E. Hohman, P. Kostenuik, C. Weaver, 2018, Bone.

Denosumab treatment is associated with decreased cortical porosity and increased bone density and strength at the proximal humerus of ovariectomized cynomolgus monkeys.

P. Kostenuik, W. B. Edwards, S. Boyd, 2022, Bone.

Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice.

P. Kostenuik, S. Morony, B. Bolon, 2004, Bone.

INFLAMMATORY BOWEL DISEASE CD 4 + CD 45 RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin

P. Kostenuik, S. Morony, D. Danilenko, 2004 .

The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft

P. Kostenuik, R. Vessella, E. Corey, 2004, Clinical & Experimental Metastasis.

Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

Sundeep Khosla, P. Kostenuik, S. Khosla, 2008, Endocrine reviews.

One Year of Transgenic Overexpression of Osteoprotegerin in Rats Suppressed Bone Resorption and Increased Vertebral Bone Volume, Density, and Strength

P. Kostenuik, M. Stolina, H. Ke, 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Receptor activator of nuclear factor кB ligand (RANKL) versus osteoprotegerin (OPG): the yin and yang of joint integrity

P. Kostenuik, V. Shalhoub, B. Bolon, 2004 .

Osteoprotegerin Reverses Osteoporosis by Inhibiting Endosteal Osteoclasts and Prevents Vascular Calcification by Blocking a Process Resembling Osteoclastogenesis

P. Kostenuik, S. Morony, D. Lacey, 2000, The Journal of experimental medicine.

Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength

P. Kostenuik, S. Morony, D. Lacey, 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Matrix Metalloproteinase–Driven Endochondral Fracture Union Proceeds Independently of Osteoclast Activity

P. Kostenuik, P. Baldock, M. McDonald, 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

The development of denosumab for the treatment of diseases of bone loss and cancer‐induced bone destruction

P. Kostenuik, W. Dougall, A. Braun, 2012, Annals of the New York Academy of Sciences.

Bone turnover markers in peripheral blood and marrow plasma reflect trabecular bone loss but not endocortical expansion in aging mice.

P. Kostenuik, M. Stolina, M. Ominsky, 2012, Bone.

Local Delivery of Recombinant Osteoprotegerin Enhances Postorthodontic Tooth Stability

P. Kostenuik, M. Stolina, S. Kapila, 2012, Calcified Tissue International.

Pharmacological mechanisms of therapeutics

P. Kostenuik, T. Rachner, L. Hofbauer, 2020 .

Skeletal Unloading Causes Resistance of Osteoprogenitor Cells to Parathyroid Hormone and to Insulin‐like Growth Factor‐I

P. Kostenuik, R. Turner, D. Bikle, 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab

P. Kostenuik, D. Lacey, W. Dougall, 2012, Nature Reviews Drug Discovery.

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism.

D L Lacey, P. Kostenuik, S. Morony, 2000, Proceedings of the National Academy of Sciences of the United States of America.

microgravity conditions Plasticity of monkey triceps muscle fibers in

B. Harrison, D. Allen, B. Girten, 2015 .

Twelve Months of Denosumab and/or Alendronate Is Associated With Improved Bone Fatigue Life, Microarchitecture, and Density in Ovariectomized Cynomolgus Monkeys

P. Kostenuik, W. B. Edwards, S. Boyd, 2022, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Why is hypercholesterolaemia so prevalent? A view from evolutionary medicine.

P. Kostenuik, U. Laufs, A. Catapano, 2018, European heart journal.

Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy.

P. Kostenuik, S. Morony, D. Lacey, 2000, Cancer research.

Sclerostin and DKK1 Inhibition Preserves and Augments Alveolar Bone Volume and Architecture in Rats with Alveolar Bone Loss

P. Kostenuik, P. Dechow, M. Stolina, 2018, Journal of dental research.

Estrogens antagonize RUNX2-mediated osteoblast-driven osteoclastogenesis through regulating RANKL membrane association.

P. Kostenuik, B. Frenkel, N. Chimge, 2015, Bone.

On the evolution and contemporary roles of bone remodeling

P. Kostenuik, 2021, Marcus and Feldman's Osteoporosis.

Osteopetrosis rescue upon RANKL administration to Rankl−/− mice: A new therapy for human RANKL‐dependent ARO

P. Kostenuik, S. Mantero, P. L. Poliani, 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

The effects of osteoprotegerin on the mechanical properties of rat bone

P. Kostenuik, T. Bateman, D. Lacey, 2001, Journal of materials science. Materials in medicine.

Genetic models in applied physiology: selected contribution: effects of spaceflight on immunity in the C57BL/6 mouse. II. Activation, cytokines, erythrocytes, and platelets.

L. Stodieck, P. Kostenuik, T. Bateman, 2003, Journal of applied physiology.

Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor.

P. Kostenuik, R. Chiusaroli, E. Schipani, 2009, The American journal of pathology.

Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia.

P. Kostenuik, S. Morony, D. Lacey, 2006, Bone.

Effects of spaceflight on murine skeletal muscle gene expression.

Louis S Stodieck, B. Harrison, D. Allen, 2009, Journal of applied physiology.

Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells

P. Kostenuik, V. Sexl, R. Erben, 2017, Scientific Reports.

Proceedings of the 2018 Santa Fe Bone Symposium: Advances in the Management of Osteoporosis.

P. Kostenuik, S. Khosla, L. Giangregorio, 2019, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.

P. Kostenuik, S. Morony, D. Lacey, 2001, Cancer research.

Lack of effect of spaceflight on bone mass and bone formation in group-housed rats.

P. Kostenuik, S. Miller, B. Halloran, 1998, Journal of applied physiology.

Genetic models in applied physiology: selected contribution: effects of spaceflight on immunity in the C57BL/6 mouse. I. Immune population distributions.

Louis S Stodieck, L. Stodieck, P. Kostenuik, 2003, Journal of applied physiology.

Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.

P. Kostenuik, A. Grauer, D. Dempster, 2012, Clinical therapeutics.

Bone and hormonal changes induced by skeletal unloading in the mature male rat.

Emily Morey-Holton, P. Kostenuik, A. Bouraoui, 1999, American journal of physiology. Endocrinology and metabolism.

Increased growth rate and tumor burden of spontaneously metastatic Walker 256 cancer cells in the skeleton of bisphosphonate-treated rats.

P. Kostenuik, F. Orr, G. Singh, 1993, Cancer research.

One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats.

P. Kostenuik, R. Guldberg, Susan Y. Smith, 2017, Bone.

Serum osteoprotegerin levels are increased in patients with advanced prostate cancer.

P. Kostenuik, R. Vessella, P. Lange, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Transient muscle paralysis degrades bone via rapid osteoclastogenesis

P. Kostenuik, M. Stolina, S. Bain, 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

RANKL inhibition: from mice to men (and women).

P. Kostenuik, W. Dougall, M. Stolina, 2007, Advances in experimental medicine and biology.

Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis

P. Kostenuik, S. Morony, J. Canon, 2007, Clinical & Experimental Metastasis.

Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption.

P. Kostenuik, R. Baron, M. Guillot, 2019, Bone.

Dickkopf‐1 regulates bone formation in young growing rodents and upon traumatic injury

P. Kostenuik, D. Lacey, T. Horan, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Combined treatment with PTH (1-34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats.

P. Kostenuik, P. Fratzl, P. Roschger, 2005, Bone.

Dual Inhibition of the Wnt Inhibitors DKK1 and Sclerostin Promotes Fracture Healing and Increases the Density and Strength of Uninjured Bone

P. Kostenuik, M. Stolina, H. Ke, 2023, The Journal of bone and joint surgery. American volume.

Local Delivery of Recombinant Osteoprotegerin Enhances Postorthodontic Tooth Stability

P. Kostenuik, M. Stolina, S. Kapila, 2012, Calcified Tissue International.

Finite Element Analysis of Denosumab Treatment Effects on Vertebral Strength in Ovariectomized Cynomolgus Monkeys

P. Kostenuik, T. Keaveny, D. Lee, 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Advances in Osteoporosis Therapy: Focus on Osteoanabolic Agents, Secondary Fracture Prevention, and Perioperative Bone Health

P. Kostenuik, P. Anderson, N. Binkley, 2023, Current Osteoporosis Reports.

Skeletal unloading inhibits the in vitro proliferation and differentiation of rat osteoprogenitor cells.

P. Kostenuik, D. Bikle, E. Morey-Holton, 1997, American Journal of Physiology.

Hypocalcemia in patients with metastatic bone disease receiving denosumab.

A. Shaywitz, P. Kostenuik, F. Saad, 2013 .

Selective adhesion of osteoblastic cells to different integrin ligands induces osteopontin gene expression.

P. Kostenuik, L. Gerstenfeld, R. Carvalho, 2003, Matrix biology : journal of the International Society for Matrix Biology.